FindTrial
Sign In

Efficacy of a herbal formulation for "PANDU NOI" (Iron Deficiency Anaemia) in Children (6-12 years of age).

Pre Clinical and Clinical Evaluation of a herbal formulation (Madhulai Manappagu) for "PANDU NOI" (Iron Deficiency Anaemia) in Children (6-12 years of age)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008235
Enrollment
70
Registered
2017-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Anaemic patients - 6 12 years of age Patients whose blood haemoglobin level is between 7.0 gms% ââ?¬â?? 10.9 gms% Health Condition 2: D509- Iron deficiency anemia, unspecified Health Condition 3: D509- Iron deficiency anemia, unspecified Health Condition 4: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Madhulai Manappagu: 1. Medicine Name: Madhulai Manappagu Ingredients Kalkandu (Sugar Candy) - equal parts, Panneer ( Rose Water) - equal parts, Madhulam Pazham Saru ( Pomegranat

Sponsors

NATIONAL INSTITUTE OF SIDDHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1.Age 6 ââ?¬â?? 12 yrs, Sex ââ?¬â?? Both male & female. 2.Patients who are willing to sign the informed consent. 3.Patients who give blood specimen for lab investigation. 4.Patients whose blood haemoglobin level is between 7.0 gms% ââ?¬â?? 10.9 gms%; MCV 5.Smear which shows hypochromic microcytic anaemia. 6.Pallor of skin, mucous membrane, conjunctiva, nail beds. 7.Lassitude, Fatigue, Shortness of breath, Palpitation. 8.Anorexia, Lack of interest, Frontal headache.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Based on Parental information and previous reports: 1.Congenital heart disease, Jaundice, bleeding disorders, Sickle cell Anaemia, Cancer, Renal failure. 2.Patients with chronic diseases, inherited defects. 3.Patients with infectious diseases. Based on Laboratory investigations: 4.Smear without the appearance of hypochromic microcytic cells. 5.Any abnormality in the blood platelet count. 6.Patients who do not give blood samples for investigation.

Design outcomes

Primary

MeasureTime frame
Primary Outcome: Increase in Hb by 2gms, Total RBC and PCV levels in investigations and symptoms reduced completely. Timepoint: 1st, 45th and 90th days of treatment—

Secondary

MeasureTime frame
Secondary Outcome: Assessed by 1.Decreased level of TIBC, ESR. 2.Increased level of Serum Iron Level. Timepoint: 1st, 45th and 90th days of treatment—

Countries

India

Contacts

Public ContactDrMMEENAKSHI SUNDARAM

National Institute of Siddha

nisdrloga@yahoo.co.in04426268112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026